{"gene":"DUSP2","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":1993,"finding":"DUSP2 (PAC-1) was cloned from human T cells as a mitogen-induced gene encoding a 32-kDa nuclear dual-specificity protein phosphatase; it localizes to the nucleus in transfected COS-7 cells and in mitogen-stimulated T cells, and is predominantly expressed in hematopoietic tissues.","method":"cDNA cloning, sequence analysis, transfection with subcellular localization by imaging","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — original cloning paper with functional domain identification and direct localization experiment, replicated across multiple subsequent studies","pmids":["7681221"],"is_preprint":false},{"year":1996,"finding":"PAC-1 transcription is induced by the MAPK/ERK pathway downstream of mitogen stimulation and oncogenic Ras/Raf signaling; an interfering ERK-2 dominant-negative mutant blocked PMA- and v-ras-dependent PAC-1 transcription, placing ERK2 upstream of PAC-1 induction. Transcriptional regulation involves an E-box element and an AP-2-related site in a 200-bp promoter region.","method":"Promoter-reporter transfection, dominant-negative ERK-2 mutant, EMSA for E-box and AP-2 binding","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — dominant-negative epistasis with reporter assays, multiple orthogonal methods in one study","pmids":["8649402"],"is_preprint":false},{"year":1995,"finding":"The DUSP2 gene encodes a nuclear dual-specificity MAP kinase phosphatase with stringent substrate specificity for MAP kinase; it downregulates intracellular signal transduction through dephosphorylation/inactivation of MAP kinases. The gene was mapped to human chromosome 2p11.2-q11.","method":"Genomic structure analysis, somatic cell hybrid mapping, in situ hybridization, SSCP linkage analysis","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chromosomal mapping with functional description, single lab","pmids":["7590752"],"is_preprint":false},{"year":2003,"finding":"The NMR solution structure of the PAC-1 C-terminal phosphatase domain revealed unique active-site geometry important for binding phosphorylated threonine and tyrosine of ERK2; structural and biochemical analyses demonstrated that dynamic interaction between the N-terminal kinase-binding domain and the C-terminal phosphatase domain is coupled to MAPK-induced conformational change of the phosphatase active site, essential for full enzymatic activity.","method":"NMR structure determination, biochemical phosphatase assays","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure with biochemical validation, single lab but multiple orthogonal methods","pmids":["12575935"],"is_preprint":false},{"year":2005,"finding":"PAC-1 in vitro dephosphorylates ERK2 but not p38α or JNK2; recombinant PAC-1 is virtually inactive alone and requires association of its N-terminal domain with ERK2 for catalytic activation. p38α interacts with but does not activate PAC-1, whereas JNK2 neither binds nor activates PAC-1. Individual mutation of conserved Arg294 and Arg295 (phosphothreonine-binding pocket) to alanine or lysine causes near-complete loss of phosphatase activity even in the presence of ERK2.","method":"In vitro phosphatase assay with recombinant proteins, active-site mutagenesis, binding assays","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis, defining substrate specificity and catalytic activation mechanism","pmids":["16288922"],"is_preprint":false},{"year":2006,"finding":"In Dusp2−/− mice, PAC-1 deficiency leads to increased JNK activity but unexpected impairment of ERK and p38 activity, reduced Elk1 transcriptional activity and reduced NFAT/AP-1 complex activity, resulting in considerably reduced inflammatory responses in the K/BxN model of rheumatoid arthritis and impaired effector immune cell function. Thus PAC-1 is a positive regulator of inflammatory signaling via JNK/ERK MAPK crosstalk.","method":"Dusp2 knockout mouse model (Dusp2−/−), K/BxN arthritis model, kinase activity assays, transcription factor reporter assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined phenotype and biochemical mechanistic readouts, multiple orthogonal methods","pmids":["16474395"],"is_preprint":false},{"year":2001,"finding":"The MAP kinase phosphatase PAC-1 (DUSP2) is recruited to and terminates ERK/MAP kinase signaling in B cells following BCR ligation primed by ES-62 (filarial nematode phosphorylcholine glycoprotein), representing a mechanism by which the parasite desensitizes B cell activation.","method":"Co-immunoprecipitation of Erk with PAC-1 after ES-62 priming and BCR ligation, phosphatase activity assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP and activity assay, single lab with functional context","pmids":["11390499"],"is_preprint":false},{"year":2004,"finding":"FcγRIIb-mediated negative regulation of BCR signaling involves rapid association of ERK with the MAP kinase phosphatase PAC-1 and dephosphorylation/inactivation of ERK; this provides a mechanism for immune-complex-mediated feedback inhibition of active antigen-driven B cell responses.","method":"Co-immunoprecipitation of ERK with PAC-1, phosphatase activity assay following FcγRIIb co-ligation","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP and activity assay, single lab, consistent with prior findings","pmids":["14607277"],"is_preprint":false},{"year":2015,"finding":"DUSP2 directly associates with STAT3 and dephosphorylates it at both Tyr705 and Ser727, thereby attenuating STAT3 activity and negatively regulating TH17 cell differentiation. DUSP2-deficient mice showed enhanced TH17 differentiation and severe susceptibility to experimental colitis.","method":"Direct co-immunoprecipitation of DUSP2 with STAT3, dephosphorylation assay, Dusp2−/− mouse colitis model, flow cytometry for TH17","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, direct dephosphorylation assay, genetic KO with defined phenotype, multiple orthogonal methods","pmids":["26479789"],"is_preprint":false},{"year":2017,"finding":"DUSP2 regulates the atypical MAP kinases ERK3 and ERK4 by direct binding via the kinase interaction motif (KIM) in the DUSP2 N-terminus and the common docking (CD) domain in ERK3/ERK4 C-termini; this interaction leads to dephosphorylation of ERK3 and ERK4 and stabilization of DUSP2. ERK4 stabilizes DUSP2 in a kinase activity-dependent manner. DUSP2 expression inhibits ERK3/ERK4-mediated activation of downstream substrate MK5.","method":"Co-immunoprecipitation, direct binding assay, dephosphorylation assays, protein stability experiments, MK5 activation assay","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding demonstrated with mechanistic domain mapping, dephosphorylation assay, functional readout via MK5, multiple orthogonal methods","pmids":["28252035"],"is_preprint":false},{"year":2017,"finding":"Hypoxia-mediated downregulation of DUSP2 is critical for accumulation of cancer stem-like cells in colorectal cancer; reduced DUSP2 leads to overproduction of COX-2-derived prostaglandin E2, which promotes cancer stemness via EP2/EP4 signaling. Genome-wide profiling revealed DUSP2-regulated genes overlap with HDAC-controlled genes.","method":"DUSP2 knockdown/overexpression, genetic/pharmacological COX-2/PGE2 pathway inhibition, tumor growth and stemness assays, genome-wide expression profiling","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with defined mechanistic pathway readout, single lab","pmids":["28652251"],"is_preprint":false},{"year":2015,"finding":"HIF-1 induces lapatinib resistance in ERBB2-positive breast cancer cells by inhibiting DUSP2, thereby maintaining ERK pathway activation in the presence of lapatinib. Overexpression of DUSP2 reverses hypoxia-mediated lapatinib resistance, demonstrating DUSP2 acts downstream of HIF-1 to suppress ERK signaling.","method":"DUSP2 overexpression/knockdown, HIF-1 stable overexpression, MEK inhibitor treatment, 3D culture apoptosis/growth assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis via overexpression rescue, multiple cell models, single lab","pmids":["25596742"],"is_preprint":false},{"year":2018,"finding":"miR-361-3p promotes EMT and metastasis in pancreatic cancer by directly targeting DUSP2 mRNA (confirmed by luciferase assay and Ago2 co-IP), leading to ERK pathway activation; re-expression of DUSP2 reverses miR-361-3p-induced EMT, establishing a miR-361-3p/DUSP2/ERK axis.","method":"Luciferase reporter assay for 3'UTR targeting, Ago2 co-immunoprecipitation, DUSP2 rescue experiments, western blot for ERK phosphorylation","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct target validation by luciferase and co-IP, rescue experiment, single lab","pmids":["30042387"],"is_preprint":false},{"year":2020,"finding":"Loss of DUSP2 in pancreatic cancer enhances proprotein convertase activity and vesicle trafficking to promote secretion of mature EV-associated VEGF-C, leading to lymphovascular invasion. Tissue-specific knockout of Dusp2 in mouse pancreas recapitulates PDAC phenotype and lymphovascular invasion.","method":"DUSP2 knockdown, tissue-specific Dusp2 knockout mouse, extracellular vesicle isolation and VEGF-C quantification, lymphatic endothelial cell functional assays","journal":"Journal of extracellular vesicles","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO with defined mechanistic readout, single lab","pmids":["32341770"],"is_preprint":false},{"year":2015,"finding":"Salubrinal acts as an inhibitor of Dusp2 (PAC1) in immune cells; partial silencing of Dusp2 downregulates IL-1β and Cox2 expression, and salubrinal suppresses Dusp2 in LPS-activated macrophages and PMA/ionomycin-activated T lymphocytes and mast cells, reducing inflammatory gene expression and arthritic responses in CAIA mice.","method":"Genome-wide microarray, qPCR, RNA interference (Dusp2 partial silencing), CAIA mouse model with clinical/histological scoring","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi knockdown with defined inflammatory phenotype, in vivo model, single lab","pmids":["25619567"],"is_preprint":false},{"year":2014,"finding":"P2Y13 receptor activation induces DUSP2 expression in cerebellar granule neurons, and the resultant DUSP2 activity dephosphorylates p38 MAPK, restoring its inactive form; cisplatin-induced sustained p38 activation correlates with progressive reduction in DUSP2 expression, suggesting DUSP2 acts to maintain p38 signaling homeostasis and neuronal survival.","method":"Microarray gene expression validated by qPCR, p38 phosphorylation assays following P2Y13 agonist treatment, knockdown of DUSP2","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptional target validation by qPCR, biochemical p38 dephosphorylation readout, single lab","pmids":["24851838"],"is_preprint":false},{"year":2022,"finding":"DUSP2 acts as a nuclear phosphatase that deactivates STAT1, thereby restricting gasdermin D (GSDMD)-mediated pyroptosis in renal tubular epithelial cells during acute kidney injury. GSDMD is a transcriptional target of activated STAT1; RTEC-specific Dusp2 deletion sensitizes mice to AKI by promoting RTEC pyroptosis. AAV-mediated DUSP2 overexpression significantly ameliorates AKI.","method":"RTEC-specific Dusp2 conditional knockout mice, AKI model, STAT1 phosphorylation assay, GSDMD transcription analysis, AAV overexpression rescue","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with defined cellular mechanism, rescue experiment, multiple orthogonal methods, in vivo validation","pmids":["35836796"],"is_preprint":false},{"year":2022,"finding":"DNTTIP1 suppresses DUSP2 gene expression by recruiting HDAC1 to the DUSP2 promoter, maintaining a deacetylated state of histone H3K27; downregulation of DUSP2 results in aberrant ERK activation and elevated MMP2 levels, promoting NPC metastasis. HDAC inhibitor chidamide restores DUSP2 expression by disrupting the DNTTIP1/HDAC1 complex.","method":"ChIP assay (HDAC1 at DUSP2 promoter), co-IP (DNTTIP1-HDAC1 interaction), luciferase reporter, western blot, in vitro/in vivo metastasis assays","journal":"EBioMedicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP and co-IP establishing epigenetic mechanism at DUSP2 promoter, functional rescue, multiple orthogonal methods","pmids":["35689852"],"is_preprint":false},{"year":2023,"finding":"DUSP2 competes with AKT1 to bind casein kinase 2 alpha 1 (CSNK2A1), thereby inhibiting AKT1 phosphorylation and promoting apoptosis in pancreatic cancer. Activated AKT1 in turn induces TRIM21 E3 ubiquitin ligase to bind and mediate ubiquitination-dependent proteasomal degradation of DUSP2, forming a positive feedback loop that suppresses DUSP2.","method":"Co-immunoprecipitation (DUSP2-CSNK2A1, AKT1-CSNK2A1, TRIM21-DUSP2), ubiquitination assay, in vitro and in vivo apoptosis assays","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP for multiple binding partners with functional readout, ubiquitination assay, single lab","pmids":["37390887"],"is_preprint":false},{"year":2017,"finding":"Hypoxia-induced downregulation of DUSP2 promotes IL-6 expression in endometriotic stromal cells, which in turn activates STAT3 phosphorylation; DUSP2 overexpression suppresses IL-6 and phospho-STAT3 levels, and DUSP2 knockdown phenocopies hypoxia-induced IL-6 upregulation, establishing a DUSP2/IL-6/STAT3 axis in endometriosis.","method":"DUSP2 knockdown/overexpression, IL-6 quantification, STAT3 phosphorylation western blot, genome-wide expression profiling, BrdU proliferation assay","journal":"American journal of reproductive immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown/overexpression with mechanistic biochemical readouts, single lab","pmids":["28440564"],"is_preprint":false},{"year":2019,"finding":"Membrane cholesterol loss during aging activates a subset of receptor tyrosine kinases (RTKs), increasing p38 MAPK activity, which in turn upregulates DUSP2 expression and activity in the hippocampus; this forms a negative-feedback loop that keeps p38 MAPK activity within physiological range during normal aging.","method":"Membrane cholesterol manipulation (enrichment/depletion), western blot for p38 phosphorylation and DUSP2 levels in aged mouse hippocampus, RTK inhibitor experiments","journal":"Frontiers in neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway dissection with pharmacological and biochemical methods, single lab","pmids":["31293510"],"is_preprint":false},{"year":2023,"finding":"DUSP2 deletion by CRISPR/Cas9 in zebrafish promotes Mauthner cell axonal regeneration at early developmental stages; DUSP2 acts as a negative regulator of axon regeneration by mediating dephosphorylation of JNK, and DUSP2 knockout slightly increases phosphorylated JNK levels. Overexpression of DUSP2 retards M-cell axon regeneration.","method":"CRISPR/Cas9 knockout, single-cell electroporation for DUSP2 overexpression, western blot for phospho-JNK, axon regeneration imaging in Tg zebrafish","journal":"Neural regeneration research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and overexpression with defined phenotype and biochemical JNK readout, single lab","pmids":["36018180"],"is_preprint":false},{"year":2024,"finding":"The RB/TRIM24 complex functions through DUSP2 as an intermediate bridge to activate the mTOR pathway in castration-resistant prostate cancer; TRIM24 transcriptional activity regulated at RB S249/T252 sites controls DUSP2 to promote mTOR signaling and prostate cancer progression.","method":"FXXXV motif mapping, co-immunoprecipitation (RB-TRIM24-DUSP2), mTOR pathway assays, PROTAC-mediated TRIM24 degradation","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP establishing ternary complex, functional mTOR pathway readout, single lab","pmids":["38514847"],"is_preprint":false},{"year":2023,"finding":"DUSP2 inhibits STAT3 phosphorylation in vivo (AAV-DUSP2 overexpression in MRL/lpr lupus nephritis mice reduces STAT3 phosphorylation) and ameliorates lupus nephritis by reducing proteinuria, inflammatory cytokines (TNF-α, IL-6, IL-1β), and renal tissue injury.","method":"AAV-mediated DUSP2 overexpression in MRL/lpr mice, western blot for STAT3 phosphorylation, proteinuria and cytokine measurement, histopathology","journal":"Open life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo overexpression with biochemical STAT3 phosphorylation readout, single lab","pmids":["37483429"],"is_preprint":false},{"year":2023,"finding":"E2F4 transcription factor binds to the DUSP2 promoter and suppresses DUSP2 expression (validated by dual-luciferase reporter and ChIP assay); DUSP2 knockdown upregulates p38 MAPK phosphorylation and promotes endothelial cell proliferation, migration, and angiogenesis under high-glucose conditions.","method":"Dual-luciferase reporter, chromatin immunoprecipitation (ChIP), western blot for p-p38 MAPK, cell proliferation/migration/tube formation assays","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms E2F4 at DUSP2 promoter, functional p38 pathway readout, single lab","pmids":["37479052"],"is_preprint":false},{"year":2025,"finding":"FBXO45 interacts with and ubiquitinates DUSP2, leading to its proteasomal degradation and subsequent ERK1/2 activation and enhanced glycolysis in cervical cancer cells (confirmed by co-IP and western blot); negative correlation between FBXO45 and DUSP2 was confirmed in tissue microarrays.","method":"Co-immunoprecipitation (FBXO45-DUSP2), ubiquitination assay, western blot for DUSP2 levels and ERK1/2 phosphorylation, Seahorse glycolysis assay, mouse xenograft model","journal":"Naunyn-Schmiedeberg's archives of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and ubiquitination assay with functional ERK/glycolysis readout, single lab","pmids":["40637745"],"is_preprint":false},{"year":2025,"finding":"NELFCD recruits PRMT5 to the DUSP2 promoter (confirmed by co-IP and ChIP), suppressing DUSP2 expression and consequently activating p38 MAPK signaling to promote colon cancer cell growth.","method":"Co-immunoprecipitation (NELFCD-PRMT5), ChIP (PRMT5 at DUSP2 promoter), RNA sequencing, DUSP2 promoter ChIP-seq, cell proliferation assays","journal":"Frontiers in bioscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and ChIP establishing transcriptional repression mechanism, functional p38 readout, single lab","pmids":["40302325"],"is_preprint":false},{"year":2003,"finding":"A variant of PAC-1 (DUSP2) identified in LGL leukemia encodes a 170-amino acid truncated protein (clone 8) lacking the phosphatase active site; when expressed as a GST fusion, this variant has no intrinsic phosphatase activity in vitro but enhances the phosphatase activity of co-added dual-specificity phosphatase CL100.","method":"cDNA library screening, GST-fusion protein expression in E. coli, in vitro phosphatase assay","journal":"Protein expression and purification","confidence":"Low","confidence_rationale":"Tier 3 / Weak — in vitro assay of variant protein, single lab, functional significance unclear","pmids":["14680939"],"is_preprint":false},{"year":2025,"finding":"IFN-I signaling in pre-exhausted T cells induces DUSP2 expression, which promotes NFAT dephosphorylation and nuclear accumulation; nuclear NFAT upregulates inhibitory receptors and antagonizes Bcl6-dependent transcriptional programs, reinforcing T cell exhaustion and impairing Tfh differentiation. Genetic ablation of Dusp2 restored CD8+ T cell function and Tfh-B cell interaction, enhancing ICB responsiveness in lung squamous carcinoma.","method":"Single-cell RNA sequencing, Dusp2 genetic ablation, NFAT phosphorylation assay, T cell functional assays, ICB treatment in Dusp2-KO mice","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined mechanistic NFAT dephosphorylation readout, single lab, scRNA-seq corroboration","pmids":["41883167"],"is_preprint":false},{"year":2025,"finding":"Flavescensine 10 exhibits a potential interaction with DUSP2 and inhibits its expression, suppressing DUSP2-mediated mitochondrial apoptosis via the PI3K/Akt/JNK pathway in APAP-induced liver injury.","method":"In vitro hepatoprotection assay, in vivo APAP liver injury model, western blot for DUSP2, PI3K/Akt/JNK pathway analysis","journal":"Acta pharmaceutica Sinica B","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological inhibition of DUSP2 with pathway readout but no direct binding confirmation, single lab","pmids":["41909738"],"is_preprint":false},{"year":2025,"finding":"Multiple oncogenic microRNA clusters (miR-17-92, miR-106a-363, miR-106b-25) directly target the DUSP2 mRNA 3'UTR (confirmed by reporter gene assay); specific miRNA inhibitors (miR-17-5p, miR-20b-5p, miR-106b-5p) increase DUSP2 mRNA levels in lymphoma cells, implicating miRNA-mediated DUSP2 suppression in MAPK pathway dysregulation in cancer.","method":"Reporter gene assay for 3'UTR interaction, pan-cancer expression correlation analysis, miRNA inhibitor treatment with qPCR","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct 3'UTR reporter assay validates miRNA binding, functional mRNA level change confirmed, single lab","pmids":["40537745"],"is_preprint":false}],"current_model":"DUSP2 (PAC-1) is a mitogen-inducible, nuclear-localized dual-specificity MAP kinase phosphatase that preferentially dephosphorylates ERK2 (requiring ERK2 binding for catalytic activation), as well as ERK3, ERK4, STAT3, and STAT1; its expression is transcriptionally induced by the ERK/MAPK pathway itself (negative feedback) and is epigenetically silenced in multiple cancers via HDAC recruitment or miRNA targeting; it acts as a positive regulator of inflammatory signaling in immune cells (through ERK/p38/JNK crosstalk), a negative regulator of TH17 differentiation and T cell exhaustion (via STAT3 and NFAT dephosphorylation), and a suppressor of tumor stemness, metastasis, and drug resistance (through control of COX-2/PGE2, VEGF-C secretion, and AKT1 signaling), while its protein stability is regulated by TRIM21- and FBXO45-mediated ubiquitination and proteasomal degradation."},"narrative":{"mechanistic_narrative":"DUSP2 (PAC-1) is a mitogen-inducible, nuclear dual-specificity MAP kinase phosphatase originally cloned from human T cells and expressed predominantly in hematopoietic tissues [PMID:7681221]. Its catalytic activity is conformationally gated: recombinant DUSP2 is essentially inactive alone and is allosterically activated upon association of its N-terminal kinase-binding domain with ERK2, a process coupled to a MAPK-induced rearrangement of the C-terminal phosphatase active site, with Arg294/Arg295 forming the phosphothreonine-binding pocket required for catalysis [PMID:12575935, PMID:16288922]. Through this binding-dependent mechanism DUSP2 preferentially dephosphorylates ERK2 while showing distinct handling of other MAPKs, and it engages the atypical kinases ERK3 and ERK4 via a KIM/CD-domain interaction that both dephosphorylates them, blocking downstream MK5 activation, and reciprocally stabilizes DUSP2 protein [PMID:16288922, PMID:28252035]. DUSP2 transcription is driven by the ERK/MAPK pathway itself, placing ERK2 upstream of PAC-1 induction and establishing a MAPK negative-feedback loop [PMID:8649402]. Beyond MAPKs, DUSP2 directly binds and dephosphorylates STAT3 (Tyr705 and Ser727) and STAT1, and modulates NFAT phosphorylation, linking it to transcriptional control of inflammatory and effector programs [PMID:26479789, PMID:35836796, PMID:41883167]. Genetic loss-of-function studies show DUSP2 is a positive regulator of inflammatory signaling via JNK/ERK crosstalk in arthritis models [PMID:16474395], a negative regulator of TH17 differentiation [PMID:26479789], a restrictor of STAT1-driven GSDMD pyroptosis in acute kidney injury [PMID:35836796], and an enforcer of T cell exhaustion downstream of type I interferon through NFAT [PMID:41883167]. In cancer, DUSP2 acts as a tumor suppressor whose silencing—via hypoxia/HIF-1, HDAC recruitment to its promoter, transcription-factor repression, or oncogenic miRNA targeting—drives ERK or p38 reactivation, stemness, EMT, metastasis, VEGF-C secretion, and drug resistance [PMID:28652251, PMID:25596742, PMID:30042387, PMID:35689852]. DUSP2 protein abundance is further controlled by ubiquitin-dependent proteasomal degradation through the E3 ligases TRIM21 and FBXO45 [PMID:37390887, PMID:40637745].","teleology":[{"year":1993,"claim":"Established the existence and basic identity of DUSP2 by cloning a mitogen-induced nuclear phosphatase, defining where and when it is expressed.","evidence":"cDNA cloning from human T cells with transfection-based subcellular localization in COS-7 and stimulated T cells","pmids":["7681221"],"confidence":"High","gaps":["Substrate specificity not yet defined","Catalytic mechanism unresolved"]},{"year":1995,"claim":"Defined DUSP2 as a MAP-kinase-directed dual-specificity phosphatase that downregulates signal transduction and mapped the gene, framing its negative-regulatory role.","evidence":"Genomic structure analysis and chromosomal mapping with functional description","pmids":["7590752"],"confidence":"Medium","gaps":["Specific MAPK substrate preference not distinguished","No structural basis for specificity"]},{"year":1996,"claim":"Showed DUSP2 transcription is itself driven by the ERK/MAPK pathway, establishing a negative-feedback architecture rather than constitutive expression.","evidence":"Promoter-reporter assays with dominant-negative ERK2 and EMSA for E-box/AP-2 elements","pmids":["8649402"],"confidence":"High","gaps":["Identity of trans-acting factors at E-box/AP-2 sites not resolved","Does not address protein-level feedback"]},{"year":2003,"claim":"Provided the structural and mechanistic basis for catalysis, showing the active site is reconfigured by N-/C-domain interaction coupled to MAPK binding.","evidence":"NMR solution structure of the C-terminal phosphatase domain with biochemical phosphatase assays","pmids":["12575935"],"confidence":"High","gaps":["No full-length structure with bound ERK2","Dynamics of activation not directly visualized"]},{"year":2005,"claim":"Defined substrate specificity and the substrate-induced activation mechanism, showing DUSP2 is inactive alone and requires ERK2 binding plus an intact phosphothreonine pocket.","evidence":"In vitro reconstitution with recombinant proteins, binding assays, and Arg294/Arg295 mutagenesis","pmids":["16288922"],"confidence":"High","gaps":["In-cell substrate repertoire beyond ERK2 not addressed","Quantitative selectivity over other DUSPs unknown"]},{"year":2006,"claim":"Revealed an unexpected in vivo role as a positive regulator of inflammation through MAPK crosstalk, complicating the simple negative-feedback model.","evidence":"Dusp2-/- mice in the K/BxN arthritis model with kinase activity and transcription-factor reporter assays","pmids":["16474395"],"confidence":"High","gaps":["Molecular basis of JNK/ERK/p38 crosstalk not fully mechanistic","Cell-type-specific contributions not separated"]},{"year":2004,"claim":"Connected DUSP2 to receptor-driven feedback inhibition, showing it is recruited to ERK to terminate B-cell signaling.","evidence":"Co-IP of ERK with PAC-1 and phosphatase assays following BCR/FcgammaRIIb or ES-62 priming","pmids":["11390499","14607277"],"confidence":"Medium","gaps":["Single-lab co-IP without reciprocal genetic validation","Recruitment mechanism not defined"]},{"year":2015,"claim":"Extended DUSP2 substrates beyond MAPKs to STAT3, defining a direct route by which it restrains TH17 differentiation.","evidence":"Reciprocal co-IP, direct dephosphorylation assays, and Dusp2-/- colitis model with flow cytometry","pmids":["26479789"],"confidence":"High","gaps":["Whether STAT3 dephosphorylation is nuclear or cytoplasmic not resolved","Selectivity for Tyr705 vs Ser727 kinetics unquantified"]},{"year":2017,"claim":"Established DUSP2 regulation of the atypical kinases ERK3/ERK4 via KIM/CD docking, with reciprocal stabilization of DUSP2, broadening its substrate range.","evidence":"Co-IP, domain-mapped binding, dephosphorylation and protein-stability assays, MK5 activation readout","pmids":["28252035"],"confidence":"High","gaps":["Physiological consequence of ERK3/ERK4 dephosphorylation in vivo unknown","Mechanism of ERK4-dependent DUSP2 stabilization not detailed"]},{"year":2017,"claim":"Defined DUSP2 as a hypoxia-suppressed tumor suppressor whose loss elevates COX-2/PGE2 to drive cancer stemness.","evidence":"DUSP2 knockdown/overexpression, COX-2/PGE2 pathway perturbation, stemness assays, genome-wide profiling","pmids":["28652251"],"confidence":"Medium","gaps":["Direct link from DUSP2 phosphatase activity to COX-2 transcription not established","Single-lab loss-of-function"]},{"year":2017,"claim":"Linked DUSP2 loss to ERK reactivation and drug resistance/inflammation across tissue contexts, positioning it downstream of HIF-1.","evidence":"DUSP2 overexpression/knockdown rescue with HIF-1 manipulation in breast cancer and endometriotic stromal cell models","pmids":["25596742","28440564"],"confidence":"Medium","gaps":["Direct substrate engagement (ERK vs STAT3) context-dependent and not always shown","Single-lab epistasis"]},{"year":2018,"claim":"Demonstrated post-transcriptional silencing of DUSP2 by oncogenic miRNAs that activates ERK to drive EMT and metastasis.","evidence":"3'UTR luciferase, Ago2 co-IP, and DUSP2 rescue in pancreatic cancer; later extended to lymphoma miRNA clusters","pmids":["30042387","40537745"],"confidence":"Medium","gaps":["Relative contribution of each miRNA in vivo unclear","Whether miRNA loss restores DUSP2 function physiologically untested"]},{"year":2020,"claim":"Identified a non-canonical route by which DUSP2 loss promotes EV-associated VEGF-C secretion and lymphovascular invasion in PDAC.","evidence":"Tissue-specific Dusp2 knockout mouse, EV isolation with VEGF-C quantification, lymphatic endothelial assays","pmids":["32341770"],"confidence":"Medium","gaps":["Phosphatase substrate driving convertase/trafficking changes not identified","Single-lab mechanism"]},{"year":2022,"claim":"Showed DUSP2 restrains STAT1-driven GSDMD pyroptosis, defining a protective role in acute kidney injury and a STAT1 substrate.","evidence":"RTEC-specific Dusp2 conditional knockout, STAT1 phosphorylation and GSDMD transcription analysis, AAV rescue","pmids":["35836796"],"confidence":"High","gaps":["Direct dephosphorylation of STAT1 by DUSP2 not shown in vitro","Tissue specificity of STAT1 vs STAT3 preference unexplained"]},{"year":2022,"claim":"Established epigenetic silencing of DUSP2 via HDAC1 recruitment to its promoter, linking chromatin state to ERK reactivation in metastasis.","evidence":"ChIP, co-IP of DNTTIP1-HDAC1, luciferase, and metastasis assays with chidamide rescue","pmids":["35689852"],"confidence":"High","gaps":["Whether HDAC silencing operates in non-NPC contexts not tested","Upstream signal controlling DNTTIP1/HDAC1 recruitment unknown"]},{"year":2023,"claim":"Identified ubiquitin-dependent control of DUSP2 stability and a competitive AKT1/CSNK2A1 mechanism, embedding DUSP2 in a self-reinforcing degradation loop.","evidence":"Co-IP of DUSP2-CSNK2A1, AKT1-CSNK2A1, TRIM21-DUSP2 and ubiquitination/apoptosis assays in pancreatic cancer","pmids":["37390887"],"confidence":"Medium","gaps":["TRIM21 ubiquitination site on DUSP2 not mapped","Single-lab multi-partner co-IP"]},{"year":2023,"claim":"Reinforced DUSP2 as a STAT3-pathway suppressor in autoimmune disease and tied additional transcription factors to its promoter repression.","evidence":"AAV-DUSP2 overexpression in lupus nephritis mice; E2F4 ChIP/luciferase at the DUSP2 promoter with p38 readout","pmids":["37483429","37479052"],"confidence":"Medium","gaps":["Direct vs indirect STAT3 effects in vivo not separated","Generality of E2F4 repression across tissues untested"]},{"year":2024,"claim":"Placed DUSP2 as an intermediate in an RB/TRIM24-mTOR signaling axis driving castration-resistant prostate cancer progression.","evidence":"Motif mapping, co-IP of the RB-TRIM24-DUSP2 complex, mTOR pathway assays, PROTAC TRIM24 degradation","pmids":["38514847"],"confidence":"Medium","gaps":["How DUSP2 phosphatase activity connects to mTOR not mechanistically defined","Single-lab ternary-complex evidence"]},{"year":2025,"claim":"Showed DUSP2 enforces T cell exhaustion downstream of type I interferon via NFAT dephosphorylation, identifying it as an immunotherapy target.","evidence":"scRNA-seq, Dusp2 genetic ablation, NFAT phosphorylation and T cell function assays, ICB treatment in vivo","pmids":["41883167"],"confidence":"Medium","gaps":["Direct DUSP2-NFAT dephosphorylation kinetics not characterized","Single tumor model"]},{"year":2025,"claim":"Added FBXO45 as a second E3 ligase degrading DUSP2 to sustain ERK-driven glycolysis, and broadened the degradation/silencing landscape.","evidence":"Co-IP, ubiquitination assay, ERK1/2 and Seahorse glycolysis readouts, xenograft, plus NELFCD/PRMT5 promoter repression","pmids":["40637745","40302325"],"confidence":"Medium","gaps":["Hierarchy/redundancy between TRIM21 and FBXO45 unknown","Degradation site on DUSP2 not mapped"]},{"year":null,"claim":"How DUSP2 selects among ERK, STAT, and NFAT substrates in a given cell type, and how its many transcriptional/epigenetic/post-translational repressors are integrated, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of substrate selection across contexts","Relative weight of transcriptional vs degradative control unquantified","No full-length DUSP2-substrate complex structure"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,2,3,4]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[4,8,9,16]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,5]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,16]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,4,9]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,8,28]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,11,17,25]}],"complexes":[],"partners":["ERK2","ERK3","ERK4","STAT3","STAT1","CSNK2A1","TRIM21","FBXO45"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q05923","full_name":"Dual specificity protein phosphatase 2","aliases":["Dual specificity protein phosphatase PAC-1"],"length_aa":314,"mass_kda":34.4,"function":"Dephosphorylates both phosphorylated Thr and Tyr residues in MAPK1, and dephosphorylation of phosphotyrosine is slightly faster than that of phosphothreonine (PubMed:8107850). Can dephosphorylate MAPK1 (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q05923/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/DUSP2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/DUSP2","total_profiled":1310},"omim":[{"mim_id":"606618","title":"DUAL-SPECIFICITY PHOSPHATASE 14; DUSP14","url":"https://www.omim.org/entry/606618"},{"mim_id":"603069","title":"DUAL-SPECIFICITY PHOSPHATASE 5; DUSP5","url":"https://www.omim.org/entry/603069"},{"mim_id":"603068","title":"DUAL-SPECIFICITY PHOSPHATASE 2; DUSP2","url":"https://www.omim.org/entry/603068"},{"mim_id":"602747","title":"DUAL-SPECIFICITY PHOSPHATASE 4; DUSP4","url":"https://www.omim.org/entry/602747"},{"mim_id":"601511","title":"SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 5A; STAT5A","url":"https://www.omim.org/entry/601511"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":122.1}],"url":"https://www.proteinatlas.org/search/DUSP2"},"hgnc":{"alias_symbol":["PAC-1"],"prev_symbol":[]},"alphafold":{"accession":"Q05923","domains":[{"cath_id":"3.40.250.10","chopping":"8-143","consensus_level":"high","plddt":92.1661,"start":8,"end":143},{"cath_id":"3.90.190.10","chopping":"171-314","consensus_level":"high","plddt":95.3487,"start":171,"end":314}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q05923","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q05923-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q05923-F1-predicted_aligned_error_v6.png","plddt_mean":90.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DUSP2","jax_strain_url":"https://www.jax.org/strain/search?query=DUSP2"},"sequence":{"accession":"Q05923","fasta_url":"https://rest.uniprot.org/uniprotkb/Q05923.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q05923/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q05923"}},"corpus_meta":[{"pmid":"7681221","id":"PMC_7681221","title":"PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase.","date":"1993","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7681221","citation_count":292,"is_preprint":false},{"pmid":"16474395","id":"PMC_16474395","title":"Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1.","date":"2006","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16474395","citation_count":219,"is_preprint":false},{"pmid":"26479789","id":"PMC_26479789","title":"The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates TH17 differentiation.","date":"2015","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26479789","citation_count":134,"is_preprint":false},{"pmid":"19281821","id":"PMC_19281821","title":"PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition.","date":"2009","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19281821","citation_count":132,"is_preprint":false},{"pmid":"19708658","id":"PMC_19708658","title":"Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3.","date":"2009","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19708658","citation_count":109,"is_preprint":false},{"pmid":"10488112","id":"PMC_10488112","title":"Pituitary adenylate cyclase-activating polypeptides directly stimulate sympathetic neuron neuropeptide Y release through PAC(1) receptor isoform activation of specific intracellular signaling pathways.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10488112","citation_count":101,"is_preprint":false},{"pmid":"8702512","id":"PMC_8702512","title":"Critical residues of integrin alphaIIb subunit for binding of alphaIIbbeta3 (glycoprotein IIb-IIIa) to fibrinogen and ligand-mimetic antibodies (PAC-1, OP-G2, and LJ-CP3).","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702512","citation_count":81,"is_preprint":false},{"pmid":"10727727","id":"PMC_10727727","title":"Developmental regulation of pituitary adenylate cyclase-activating polypeptide and PAC(1) receptor mRNA expression in the rat central nervous system.","date":"2000","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10727727","citation_count":79,"is_preprint":false},{"pmid":"30042387","id":"PMC_30042387","title":"MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30042387","citation_count":77,"is_preprint":false},{"pmid":"8649402","id":"PMC_8649402","title":"Activation of the mitogen-activated protein kinase pathway induces transcription of the PAC-1 phosphatase gene.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8649402","citation_count":73,"is_preprint":false},{"pmid":"26658840","id":"PMC_26658840","title":"Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.","date":"2015","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/26658840","citation_count":70,"is_preprint":false},{"pmid":"30088106","id":"PMC_30088106","title":"PACAP38 and PAC1 receptor blockade: a new target for headache?","date":"2018","source":"The journal of headache and pain","url":"https://pubmed.ncbi.nlm.nih.gov/30088106","citation_count":64,"is_preprint":false},{"pmid":"28652251","id":"PMC_28652251","title":"Hypoxia-Induced Downregulation of DUSP-2 Phosphatase Drives Colon Cancer Stemness.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28652251","citation_count":58,"is_preprint":false},{"pmid":"30213827","id":"PMC_30213827","title":"JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma.","date":"2018","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/30213827","citation_count":49,"is_preprint":false},{"pmid":"24357799","id":"PMC_24357799","title":"ERO1α-dependent endoplasmic reticulum-mitochondrial calcium flux contributes to ER stress and mitochondrial permeabilization by procaspase-activating compound-1 (PAC-1).","date":"2013","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24357799","citation_count":44,"is_preprint":false},{"pmid":"11353814","id":"PMC_11353814","title":"ADP-ribosylation factor-dependent phospholipase D activation by VPAC receptors and a PAC(1) receptor splice variant.","date":"2001","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11353814","citation_count":44,"is_preprint":false},{"pmid":"12575935","id":"PMC_12575935","title":"Solution structure of the MAPK phosphatase PAC-1 catalytic domain. Insights into substrate-induced enzymatic activation of MKP.","date":"2003","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/12575935","citation_count":44,"is_preprint":false},{"pmid":"25596742","id":"PMC_25596742","title":"Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25596742","citation_count":42,"is_preprint":false},{"pmid":"32341770","id":"PMC_32341770","title":"DUSP2 regulates extracellular vesicle-VEGF-C secretion and pancreatic cancer early dissemination.","date":"2020","source":"Journal of extracellular vesicles","url":"https://pubmed.ncbi.nlm.nih.gov/32341770","citation_count":40,"is_preprint":false},{"pmid":"19640007","id":"PMC_19640007","title":"Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition.","date":"2009","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19640007","citation_count":40,"is_preprint":false},{"pmid":"10648899","id":"PMC_10648899","title":"Cellular distribution of the splice variants of the receptor for pituitary adenylate cyclase-activating polypeptide (PAC(1)-R) in the rat brain by in situ RT-PCR.","date":"2000","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10648899","citation_count":39,"is_preprint":false},{"pmid":"25792385","id":"PMC_25792385","title":"Curcumin enhances the radiosensitivity of U87 cells by inducing DUSP-2 up-regulation.","date":"2015","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25792385","citation_count":38,"is_preprint":false},{"pmid":"35836796","id":"PMC_35836796","title":"DUSP2-mediated inhibition of tubular epithelial cell pyroptosis confers nephroprotection in acute kidney injury.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/35836796","citation_count":37,"is_preprint":false},{"pmid":"11390499","id":"PMC_11390499","title":"A filarial nematode-secreted phosphorylcholine-containing glycoprotein uncouples the B cell antigen receptor from extracellular signal-regulated kinase-mitogen-activated protein kinase by promoting the surface Ig-mediated recruitment of Src homology 2 domain-containing tyrosine phosphatase-1 and Pac-1 mitogen-activated kinase-phosphatase.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11390499","citation_count":35,"is_preprint":false},{"pmid":"26630918","id":"PMC_26630918","title":"Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities.","date":"2016","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26630918","citation_count":34,"is_preprint":false},{"pmid":"35689852","id":"PMC_35689852","title":"DNTTIP1 promotes nasopharyngeal carcinoma metastasis via recruiting HDAC1 to DUSP2 promoter and activating ERK signaling pathway.","date":"2022","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/35689852","citation_count":33,"is_preprint":false},{"pmid":"11032869","id":"PMC_11032869","title":"Mice with markedly reduced PACAP (PAC(1)) receptor expression by targeted deletion of the signal peptide.","date":"2000","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11032869","citation_count":33,"is_preprint":false},{"pmid":"10891585","id":"PMC_10891585","title":"Progesterone increases mRNA levels of pituitary adenylate cyclase-activating polypeptide (PACAP) and type I PACAP receptor (PAC(1)) in the rat hypothalamus.","date":"2000","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10891585","citation_count":33,"is_preprint":false},{"pmid":"16288922","id":"PMC_16288922","title":"New insights into the catalytic activation of the MAPK phosphatase PAC-1 induced by its substrate MAPK ERK2 binding.","date":"2005","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16288922","citation_count":33,"is_preprint":false},{"pmid":"25619567","id":"PMC_25619567","title":"Salubrinal acts as a Dusp2 inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25619567","citation_count":32,"is_preprint":false},{"pmid":"20499133","id":"PMC_20499133","title":"Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs.","date":"2010","source":"Investigational new drugs","url":"https://pubmed.ncbi.nlm.nih.gov/20499133","citation_count":32,"is_preprint":false},{"pmid":"28440564","id":"PMC_28440564","title":"Hypoxia-inhibited DUSP2 expression promotes IL-6/STAT3 signaling in endometriosis.","date":"2017","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/28440564","citation_count":29,"is_preprint":false},{"pmid":"22007686","id":"PMC_22007686","title":"Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1).","date":"2011","source":"ACS combinatorial science","url":"https://pubmed.ncbi.nlm.nih.gov/22007686","citation_count":29,"is_preprint":false},{"pmid":"24851838","id":"PMC_24851838","title":"Neuroprotection elicited by P2Y13 receptors against genotoxic stress by inducing DUSP2 expression and MAPK signaling recovery.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24851838","citation_count":27,"is_preprint":false},{"pmid":"28252035","id":"PMC_28252035","title":"Regulation of atypical MAP kinases ERK3 and ERK4 by the phosphatase DUSP2.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28252035","citation_count":26,"is_preprint":false},{"pmid":"37390887","id":"PMC_37390887","title":"DUSP2 recruits CSNK2A1 to suppress AKT1-mediated apoptosis resistance under hypoxic microenvironment in pancreatic cancer.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37390887","citation_count":22,"is_preprint":false},{"pmid":"11208582","id":"PMC_11208582","title":"Role of PAC(1) receptor in adrenal catecholamine secretion induced by PACAP and VIP in vivo.","date":"2001","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11208582","citation_count":20,"is_preprint":false},{"pmid":"14607277","id":"PMC_14607277","title":"FcgammaRIIb-mediated negative regulation of BCR signalling is associated with the recruitment of the MAPkinase-phosphatase, Pac-1, and the 3'-inositol phosphatase, PTEN.","date":"2004","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/14607277","citation_count":19,"is_preprint":false},{"pmid":"11118531","id":"PMC_11118531","title":"Desensitization, surface expression, and glycosylation of a functional, epitope-tagged type I PACAP (PAC(1)) receptor.","date":"2000","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11118531","citation_count":19,"is_preprint":false},{"pmid":"7590752","id":"PMC_7590752","title":"Genomic organization and chromosomal localization of the DUSP2 gene, encoding a MAP kinase phosphatase, to human 2p11.2-q11.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7590752","citation_count":18,"is_preprint":false},{"pmid":"30011263","id":"PMC_30011263","title":"miR-106a Reduces 5-Fluorouracil (5-FU) Sensitivity of Colorectal Cancer by Targeting Dual-Specificity Phosphatases 2 (DUSP2).","date":"2018","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/30011263","citation_count":18,"is_preprint":false},{"pmid":"35295342","id":"PMC_35295342","title":"The SKA3-DUSP2 Axis Promotes Gastric Cancer Tumorigenesis and Epithelial-Mesenchymal Transition by Activating the MAPK/ERK Pathway.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35295342","citation_count":17,"is_preprint":false},{"pmid":"31527025","id":"PMC_31527025","title":"Acquisition of class C β-lactamase PAC-1 by ST664 strains of Pseudomonas aeruginosa.","date":"2019","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/31527025","citation_count":17,"is_preprint":false},{"pmid":"25754465","id":"PMC_25754465","title":"Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell apoptosis.","date":"2015","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25754465","citation_count":17,"is_preprint":false},{"pmid":"25856364","id":"PMC_25856364","title":"Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics.","date":"2015","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25856364","citation_count":16,"is_preprint":false},{"pmid":"30859090","id":"PMC_30859090","title":"Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30859090","citation_count":15,"is_preprint":false},{"pmid":"37543479","id":"PMC_37543479","title":"Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research.","date":"2023","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37543479","citation_count":14,"is_preprint":false},{"pmid":"32635530","id":"PMC_32635530","title":"Novel Chrysin-De-Allyl PAC-1 Hybrid Analogues as Anticancer Compounds: Design, Synthesis, and Biological Evaluation.","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32635530","citation_count":13,"is_preprint":false},{"pmid":"31889045","id":"PMC_31889045","title":"Expression of Dual-Specificity Phosphatase 2 (DUSP2) in Patients with Serous Ovarian Carcinoma and in SKOV3 and OVCAR3 Cells In Vitro.","date":"2019","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/31889045","citation_count":12,"is_preprint":false},{"pmid":"25046380","id":"PMC_25046380","title":"PAC-1 and isatin derivatives are weak matrix metalloproteinase inhibitors.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25046380","citation_count":12,"is_preprint":false},{"pmid":"31085235","id":"PMC_31085235","title":"PACAP stimulates insulin secretion by PAC1 receptor and ion channels in β-cells.","date":"2019","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/31085235","citation_count":12,"is_preprint":false},{"pmid":"11035203","id":"PMC_11035203","title":"Splice variants of PAC(1) receptor during early neural development of rats.","date":"2000","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/11035203","citation_count":12,"is_preprint":false},{"pmid":"24030118","id":"PMC_24030118","title":"Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin.","date":"2013","source":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/24030118","citation_count":12,"is_preprint":false},{"pmid":"7723634","id":"PMC_7723634","title":"The dual specificity phosphatase PAC-1 is transcriptionally induced in the rat brain following transient forebrain ischemia.","date":"1995","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/7723634","citation_count":12,"is_preprint":false},{"pmid":"36430275","id":"PMC_36430275","title":"PAC1, VPAC1, and VPAC2 Receptor Expression in Rat and Human Trigeminal Ganglia: Characterization of PACAP-Responsive Receptor Antibodies.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36430275","citation_count":11,"is_preprint":false},{"pmid":"22612450","id":"PMC_22612450","title":"Activation of PAC(1) and VPAC receptor subtypes elicits differential physiological responses from sympathetic preganglionic neurons in the anaesthetized rat.","date":"2012","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22612450","citation_count":11,"is_preprint":false},{"pmid":"23859779","id":"PMC_23859779","title":"Synthesis and initial in vitro biological evaluation of two new zinc-chelating compounds: comparison with TPEN and PAC-1.","date":"2013","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23859779","citation_count":11,"is_preprint":false},{"pmid":"1721684","id":"PMC_1721684","title":"PAC 1: an epitope associated with two novel glycoprotein components of isolated postsynaptic densities and a novel cytoskeleton-associated polypeptide.","date":"1991","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/1721684","citation_count":11,"is_preprint":false},{"pmid":"38616050","id":"PMC_38616050","title":"Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC1 receptor.","date":"2024","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38616050","citation_count":10,"is_preprint":false},{"pmid":"12409233","id":"PMC_12409233","title":"Specific interaction between the hop1 intracellular loop 3 domain of the human PAC(1) receptor and ARF.","date":"2002","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/12409233","citation_count":9,"is_preprint":false},{"pmid":"26257207","id":"PMC_26257207","title":"Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells.","date":"2015","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/26257207","citation_count":9,"is_preprint":false},{"pmid":"37479052","id":"PMC_37479052","title":"Interfering with Dusp2 alleviates high glucose-induced vascular endothelial cell dysfunction by promoting p38 MAPK pathway activation.","date":"2023","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/37479052","citation_count":8,"is_preprint":false},{"pmid":"27488460","id":"PMC_27488460","title":"SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis.","date":"2016","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27488460","citation_count":8,"is_preprint":false},{"pmid":"26658105","id":"PMC_26658105","title":"Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26658105","citation_count":8,"is_preprint":false},{"pmid":"28065858","id":"PMC_28065858","title":"Role of transglutaminase 2 in PAC1 receptor mediated protection against hypoxia-induced cell death and neurite outgrowth in differentiating N2a neuroblastoma cells.","date":"2017","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28065858","citation_count":8,"is_preprint":false},{"pmid":"37738028","id":"PMC_37738028","title":"The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma.","date":"2023","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/37738028","citation_count":7,"is_preprint":false},{"pmid":"34365722","id":"PMC_34365722","title":"Apatinib combined with Keytruda treatment induces apoptosis of gastric carcinoma cells through CES4/miR-616-5p/DUSP2 axis.","date":"2021","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/34365722","citation_count":7,"is_preprint":false},{"pmid":"38556137","id":"PMC_38556137","title":"C. elegans Afadin is required for epidermal morphogenesis and functionally interfaces with the cadherin-catenin complex and RhoGAP PAC-1/ARHGAP21.","date":"2024","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/38556137","citation_count":7,"is_preprint":false},{"pmid":"16388318","id":"PMC_16388318","title":"Ligand-mimetic anti-alphaIIb beta3 antibody PAC-1 inhibits tyrosine signaling, proliferation and lung colonization of melanoma cells.","date":"2005","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/16388318","citation_count":7,"is_preprint":false},{"pmid":"27745706","id":"PMC_27745706","title":"PKA, novel PKC isoforms, and ERK is mediating PACAP auto-regulation via PAC1R in human neuroblastoma NB-1 cells.","date":"2016","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/27745706","citation_count":7,"is_preprint":false},{"pmid":"26620316","id":"PMC_26620316","title":"Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299.","date":"2015","source":"Asia-Pacific journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26620316","citation_count":7,"is_preprint":false},{"pmid":"38514847","id":"PMC_38514847","title":"Retinoblastoma-associated protein is important for TRIM24-mediated activation of the mTOR signaling pathway through DUSP2 action in prostate cancer.","date":"2024","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/38514847","citation_count":6,"is_preprint":false},{"pmid":"36018180","id":"PMC_36018180","title":"DUSP2 deletion with CRISPR/Cas9 promotes Mauthner cell axonal regeneration at the early stage of zebrafish.","date":"2023","source":"Neural regeneration research","url":"https://pubmed.ncbi.nlm.nih.gov/36018180","citation_count":6,"is_preprint":false},{"pmid":"29269017","id":"PMC_29269017","title":"PAC-1 and its derivative WF-210 Inhibit Angiogenesis by inhibiting VEGF/VEGFR pathway.","date":"2017","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29269017","citation_count":6,"is_preprint":false},{"pmid":"25375135","id":"PMC_25375135","title":"The dual-specificity phosphatase 2 (DUSP2) does not regulate obesity-associated inflammation or insulin resistance in mice.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25375135","citation_count":6,"is_preprint":false},{"pmid":"19513289","id":"PMC_19513289","title":"Cilostazol reduces PAC-1 expression on platelets in ischemic stroke.","date":"2008","source":"Journal of clinical neurology (Seoul, Korea)","url":"https://pubmed.ncbi.nlm.nih.gov/19513289","citation_count":6,"is_preprint":false},{"pmid":"30094257","id":"PMC_30094257","title":"DUSP2 methylation is a candidate biomarker of outcome in head and neck cancer.","date":"2018","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30094257","citation_count":5,"is_preprint":false},{"pmid":"37483429","id":"PMC_37483429","title":"DUSP2 inhibits the progression of lupus nephritis in mice by regulating the STAT3 pathway.","date":"2023","source":"Open life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37483429","citation_count":4,"is_preprint":false},{"pmid":"33285319","id":"PMC_33285319","title":"Proteomic changes in Trypanosoma cruzi epimastigotes treated with the proapoptotic compound PAC-1.","date":"2020","source":"Biochimica et biophysica acta. Proteins and proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/33285319","citation_count":4,"is_preprint":false},{"pmid":"7512700","id":"PMC_7512700","title":"Expression of PAC 1, an epitope associated with two synapse-enriched glycoproteins and a neuronal cytoskeleton-associated polypeptide in developing forebrain neurons.","date":"1994","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/7512700","citation_count":4,"is_preprint":false},{"pmid":"14680939","id":"PMC_14680939","title":"Characterization of a variant of PAC-1 in large granular lymphocyte leukemia.","date":"2003","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/14680939","citation_count":4,"is_preprint":false},{"pmid":"31293510","id":"PMC_31293510","title":"Aging Increases Hippocampal DUSP2 by a Membrane Cholesterol Loss-Mediated RTK/p38MAPK Activation Mechanism.","date":"2019","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31293510","citation_count":4,"is_preprint":false},{"pmid":"30273837","id":"PMC_30273837","title":"Pharmacokinetics, tissue distribution and plasma protein binding study of SM-1, a novel PAC-1 derivative.","date":"2018","source":"Journal of pharmaceutical and biomedical analysis","url":"https://pubmed.ncbi.nlm.nih.gov/30273837","citation_count":3,"is_preprint":false},{"pmid":"18569522","id":"PMC_18569522","title":"Does structural commonality of metal complex formation by PAC-1 (anticancer), DHBNH (anti-HIV), AHL (autoinducer), and UCS1025A (anticancer) denote mechanistic similarity? Signal transduction and medical aspects.","date":"2008","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/18569522","citation_count":3,"is_preprint":false},{"pmid":"38010777","id":"PMC_38010777","title":"Mathematical modeling predicts pathways to successful implementation of combination TRAIL-producing oncolytic virus and PAC-1 to treat granulosa cell tumors of the ovary.","date":"2023","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38010777","citation_count":3,"is_preprint":false},{"pmid":"40537745","id":"PMC_40537745","title":"The MAP kinase negative regulator DUSP2 (dual specificity phosphatase 2) is controlled by oncogenic microRNA cluster miR-17-92, miR-106a-363 and miR-106b-25.","date":"2025","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40537745","citation_count":2,"is_preprint":false},{"pmid":"37909756","id":"PMC_37909756","title":"First report of environmental bla PAC-1-carrying Aeromonas enteropelogenes.","date":"2023","source":"Microbiology spectrum","url":"https://pubmed.ncbi.nlm.nih.gov/37909756","citation_count":2,"is_preprint":false},{"pmid":"38513057","id":"PMC_38513057","title":"Circ-EIF3I Promotes Hepatocellular Carcinoma Progression Through Modulating miR-361-3p/DUSP2 Axis.","date":"2024","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/38513057","citation_count":2,"is_preprint":false},{"pmid":"35621246","id":"PMC_35621246","title":"First-in-human development of a pharmacodynamic biomarker for PAC1 receptor antagonists using intradermal injections of maxadilan.","date":"2022","source":"Clinical and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/35621246","citation_count":2,"is_preprint":false},{"pmid":"21608218","id":"PMC_21608218","title":"[Effect of electro-needling at acupoints of the yangming meridian on the expression of PAC-1 and lower limb functions in acute cerebral infarction patients].","date":"2011","source":"Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21608218","citation_count":2,"is_preprint":false},{"pmid":"40242587","id":"PMC_40242587","title":"PAC-1 Synergizes with Sunitinib to Enhance Cell Death in Pancreatic Neuroendocrine Tumors.","date":"2025","source":"ACS pharmacology & translational science","url":"https://pubmed.ncbi.nlm.nih.gov/40242587","citation_count":1,"is_preprint":false},{"pmid":"37546884","id":"PMC_37546884","title":"C. elegans Afadin is required for epidermal morphogenesis and functionally interfaces with the cadherin-catenin complex and RhoGAP PAC-1/ARHGAP21.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37546884","citation_count":1,"is_preprint":false},{"pmid":"24844962","id":"PMC_24844962","title":"[Changes and significance of P-selectin and PAC-1 in coronary heart disease before and after stenting].","date":"2014","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/24844962","citation_count":1,"is_preprint":false},{"pmid":"41909738","id":"PMC_41909738","title":"Flavescensines A-L: Novel azaspiro[4.4] heterodimeric alkaloids from Sophora flavescens protect against liver injury by inhibiting DUSP2-mediated mitochondrial apoptosis.","date":"2025","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/41909738","citation_count":1,"is_preprint":false},{"pmid":"40302325","id":"PMC_40302325","title":"NELFCD Promotes Colon Cancer Progression by Regulating the DUSP2-p38 Axis.","date":"2025","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/40302325","citation_count":0,"is_preprint":false},{"pmid":"40637745","id":"PMC_40637745","title":"FBXO45 enhances cell viability and glycolysis in cervical cancer via DUSP2 ubiquitination-mediated ERK1/2 activation.","date":"2025","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40637745","citation_count":0,"is_preprint":false},{"pmid":"41883167","id":"PMC_41883167","title":"The phosphatase DUSP2 constrains lymphoid remodeling and immunotherapy response in lung squamous carcinoma.","date":"2026","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/41883167","citation_count":0,"is_preprint":false},{"pmid":"41702189","id":"PMC_41702189","title":"PACAP/PAC 1 modulates light-induced sleep via the ipRGC-VLPO pathway.","date":"2026","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/41702189","citation_count":0,"is_preprint":false},{"pmid":"42084878","id":"PMC_42084878","title":"LGL-1 and the RhoGAP protein PAC-1 redundantly polarize the Caenorhabditis elegans embryonic epidermis.","date":"2026","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/42084878","citation_count":0,"is_preprint":false},{"pmid":"41890132","id":"PMC_41890132","title":"LGL-1 and the RhoGAP protein PAC-1 redundantly polarize the C. elegans embryonic epidermis.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41890132","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51853,"output_tokens":8200,"usd":0.13928,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17367,"output_tokens":5771,"usd":0.115555,"stage2_stop_reason":"end_turn"},"total_usd":0.254835,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"I need to carefully classify each paper before extracting. Many papers in this corpus are about:\n1. DUSP2/PAC-1 (the human dual-specificity phosphatase, gene DUSP2) - INCLUDE\n2. PAC-1 (procaspase-activating compound 1, a small molecule drug) - EXCLUDE (different entity)\n3. PAC(1) receptor (PACAP receptor type 1) - EXCLUDE (different gene, ADCYAP1R1)\n4. PAC-1 antibody (anti-integrin αIIbβ3 antibody) - EXCLUDE (different entity)\n5. PAC-1/ARHGAP21 (C. elegans RhoGAP) - EXCLUDE (different gene, symbol collision)\n6. bla PAC-1 (β-lactamase) - EXCLUDE (microbial gene collision)\n\nPapers about DUSP2/PAC-1 phosphatase: [1], [2], [3], [10], [17], [24], [29], [30], [34], [35], [38], [40], [54], [62], [73], [75], [81], [82], [86], [95], [96], [97]\n\nAlso potentially relevant: [9], [13], [18], [19], [22], [23], [26], [32], [36], [42], [94]\n\nLet me now extract discoveries:\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"DUSP2 (PAC-1) was cloned from human T cells as a mitogen-induced gene encoding a 32-kDa nuclear dual-specificity protein phosphatase; it localizes to the nucleus in transfected COS-7 cells and in mitogen-stimulated T cells, and is predominantly expressed in hematopoietic tissues.\",\n      \"method\": \"cDNA cloning, sequence analysis, transfection with subcellular localization by imaging\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — original cloning paper with functional domain identification and direct localization experiment, replicated across multiple subsequent studies\",\n      \"pmids\": [\"7681221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"PAC-1 transcription is induced by the MAPK/ERK pathway downstream of mitogen stimulation and oncogenic Ras/Raf signaling; an interfering ERK-2 dominant-negative mutant blocked PMA- and v-ras-dependent PAC-1 transcription, placing ERK2 upstream of PAC-1 induction. Transcriptional regulation involves an E-box element and an AP-2-related site in a 200-bp promoter region.\",\n      \"method\": \"Promoter-reporter transfection, dominant-negative ERK-2 mutant, EMSA for E-box and AP-2 binding\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — dominant-negative epistasis with reporter assays, multiple orthogonal methods in one study\",\n      \"pmids\": [\"8649402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The DUSP2 gene encodes a nuclear dual-specificity MAP kinase phosphatase with stringent substrate specificity for MAP kinase; it downregulates intracellular signal transduction through dephosphorylation/inactivation of MAP kinases. The gene was mapped to human chromosome 2p11.2-q11.\",\n      \"method\": \"Genomic structure analysis, somatic cell hybrid mapping, in situ hybridization, SSCP linkage analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chromosomal mapping with functional description, single lab\",\n      \"pmids\": [\"7590752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The NMR solution structure of the PAC-1 C-terminal phosphatase domain revealed unique active-site geometry important for binding phosphorylated threonine and tyrosine of ERK2; structural and biochemical analyses demonstrated that dynamic interaction between the N-terminal kinase-binding domain and the C-terminal phosphatase domain is coupled to MAPK-induced conformational change of the phosphatase active site, essential for full enzymatic activity.\",\n      \"method\": \"NMR structure determination, biochemical phosphatase assays\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure with biochemical validation, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"12575935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PAC-1 in vitro dephosphorylates ERK2 but not p38α or JNK2; recombinant PAC-1 is virtually inactive alone and requires association of its N-terminal domain with ERK2 for catalytic activation. p38α interacts with but does not activate PAC-1, whereas JNK2 neither binds nor activates PAC-1. Individual mutation of conserved Arg294 and Arg295 (phosphothreonine-binding pocket) to alanine or lysine causes near-complete loss of phosphatase activity even in the presence of ERK2.\",\n      \"method\": \"In vitro phosphatase assay with recombinant proteins, active-site mutagenesis, binding assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis, defining substrate specificity and catalytic activation mechanism\",\n      \"pmids\": [\"16288922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In Dusp2−/− mice, PAC-1 deficiency leads to increased JNK activity but unexpected impairment of ERK and p38 activity, reduced Elk1 transcriptional activity and reduced NFAT/AP-1 complex activity, resulting in considerably reduced inflammatory responses in the K/BxN model of rheumatoid arthritis and impaired effector immune cell function. Thus PAC-1 is a positive regulator of inflammatory signaling via JNK/ERK MAPK crosstalk.\",\n      \"method\": \"Dusp2 knockout mouse model (Dusp2−/−), K/BxN arthritis model, kinase activity assays, transcription factor reporter assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined phenotype and biochemical mechanistic readouts, multiple orthogonal methods\",\n      \"pmids\": [\"16474395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The MAP kinase phosphatase PAC-1 (DUSP2) is recruited to and terminates ERK/MAP kinase signaling in B cells following BCR ligation primed by ES-62 (filarial nematode phosphorylcholine glycoprotein), representing a mechanism by which the parasite desensitizes B cell activation.\",\n      \"method\": \"Co-immunoprecipitation of Erk with PAC-1 after ES-62 priming and BCR ligation, phosphatase activity assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP and activity assay, single lab with functional context\",\n      \"pmids\": [\"11390499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FcγRIIb-mediated negative regulation of BCR signaling involves rapid association of ERK with the MAP kinase phosphatase PAC-1 and dephosphorylation/inactivation of ERK; this provides a mechanism for immune-complex-mediated feedback inhibition of active antigen-driven B cell responses.\",\n      \"method\": \"Co-immunoprecipitation of ERK with PAC-1, phosphatase activity assay following FcγRIIb co-ligation\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP and activity assay, single lab, consistent with prior findings\",\n      \"pmids\": [\"14607277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DUSP2 directly associates with STAT3 and dephosphorylates it at both Tyr705 and Ser727, thereby attenuating STAT3 activity and negatively regulating TH17 cell differentiation. DUSP2-deficient mice showed enhanced TH17 differentiation and severe susceptibility to experimental colitis.\",\n      \"method\": \"Direct co-immunoprecipitation of DUSP2 with STAT3, dephosphorylation assay, Dusp2−/− mouse colitis model, flow cytometry for TH17\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, direct dephosphorylation assay, genetic KO with defined phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"26479789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DUSP2 regulates the atypical MAP kinases ERK3 and ERK4 by direct binding via the kinase interaction motif (KIM) in the DUSP2 N-terminus and the common docking (CD) domain in ERK3/ERK4 C-termini; this interaction leads to dephosphorylation of ERK3 and ERK4 and stabilization of DUSP2. ERK4 stabilizes DUSP2 in a kinase activity-dependent manner. DUSP2 expression inhibits ERK3/ERK4-mediated activation of downstream substrate MK5.\",\n      \"method\": \"Co-immunoprecipitation, direct binding assay, dephosphorylation assays, protein stability experiments, MK5 activation assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding demonstrated with mechanistic domain mapping, dephosphorylation assay, functional readout via MK5, multiple orthogonal methods\",\n      \"pmids\": [\"28252035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hypoxia-mediated downregulation of DUSP2 is critical for accumulation of cancer stem-like cells in colorectal cancer; reduced DUSP2 leads to overproduction of COX-2-derived prostaglandin E2, which promotes cancer stemness via EP2/EP4 signaling. Genome-wide profiling revealed DUSP2-regulated genes overlap with HDAC-controlled genes.\",\n      \"method\": \"DUSP2 knockdown/overexpression, genetic/pharmacological COX-2/PGE2 pathway inhibition, tumor growth and stemness assays, genome-wide expression profiling\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with defined mechanistic pathway readout, single lab\",\n      \"pmids\": [\"28652251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HIF-1 induces lapatinib resistance in ERBB2-positive breast cancer cells by inhibiting DUSP2, thereby maintaining ERK pathway activation in the presence of lapatinib. Overexpression of DUSP2 reverses hypoxia-mediated lapatinib resistance, demonstrating DUSP2 acts downstream of HIF-1 to suppress ERK signaling.\",\n      \"method\": \"DUSP2 overexpression/knockdown, HIF-1 stable overexpression, MEK inhibitor treatment, 3D culture apoptosis/growth assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis via overexpression rescue, multiple cell models, single lab\",\n      \"pmids\": [\"25596742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-361-3p promotes EMT and metastasis in pancreatic cancer by directly targeting DUSP2 mRNA (confirmed by luciferase assay and Ago2 co-IP), leading to ERK pathway activation; re-expression of DUSP2 reverses miR-361-3p-induced EMT, establishing a miR-361-3p/DUSP2/ERK axis.\",\n      \"method\": \"Luciferase reporter assay for 3'UTR targeting, Ago2 co-immunoprecipitation, DUSP2 rescue experiments, western blot for ERK phosphorylation\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct target validation by luciferase and co-IP, rescue experiment, single lab\",\n      \"pmids\": [\"30042387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Loss of DUSP2 in pancreatic cancer enhances proprotein convertase activity and vesicle trafficking to promote secretion of mature EV-associated VEGF-C, leading to lymphovascular invasion. Tissue-specific knockout of Dusp2 in mouse pancreas recapitulates PDAC phenotype and lymphovascular invasion.\",\n      \"method\": \"DUSP2 knockdown, tissue-specific Dusp2 knockout mouse, extracellular vesicle isolation and VEGF-C quantification, lymphatic endothelial cell functional assays\",\n      \"journal\": \"Journal of extracellular vesicles\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO with defined mechanistic readout, single lab\",\n      \"pmids\": [\"32341770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Salubrinal acts as an inhibitor of Dusp2 (PAC1) in immune cells; partial silencing of Dusp2 downregulates IL-1β and Cox2 expression, and salubrinal suppresses Dusp2 in LPS-activated macrophages and PMA/ionomycin-activated T lymphocytes and mast cells, reducing inflammatory gene expression and arthritic responses in CAIA mice.\",\n      \"method\": \"Genome-wide microarray, qPCR, RNA interference (Dusp2 partial silencing), CAIA mouse model with clinical/histological scoring\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi knockdown with defined inflammatory phenotype, in vivo model, single lab\",\n      \"pmids\": [\"25619567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"P2Y13 receptor activation induces DUSP2 expression in cerebellar granule neurons, and the resultant DUSP2 activity dephosphorylates p38 MAPK, restoring its inactive form; cisplatin-induced sustained p38 activation correlates with progressive reduction in DUSP2 expression, suggesting DUSP2 acts to maintain p38 signaling homeostasis and neuronal survival.\",\n      \"method\": \"Microarray gene expression validated by qPCR, p38 phosphorylation assays following P2Y13 agonist treatment, knockdown of DUSP2\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptional target validation by qPCR, biochemical p38 dephosphorylation readout, single lab\",\n      \"pmids\": [\"24851838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DUSP2 acts as a nuclear phosphatase that deactivates STAT1, thereby restricting gasdermin D (GSDMD)-mediated pyroptosis in renal tubular epithelial cells during acute kidney injury. GSDMD is a transcriptional target of activated STAT1; RTEC-specific Dusp2 deletion sensitizes mice to AKI by promoting RTEC pyroptosis. AAV-mediated DUSP2 overexpression significantly ameliorates AKI.\",\n      \"method\": \"RTEC-specific Dusp2 conditional knockout mice, AKI model, STAT1 phosphorylation assay, GSDMD transcription analysis, AAV overexpression rescue\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with defined cellular mechanism, rescue experiment, multiple orthogonal methods, in vivo validation\",\n      \"pmids\": [\"35836796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DNTTIP1 suppresses DUSP2 gene expression by recruiting HDAC1 to the DUSP2 promoter, maintaining a deacetylated state of histone H3K27; downregulation of DUSP2 results in aberrant ERK activation and elevated MMP2 levels, promoting NPC metastasis. HDAC inhibitor chidamide restores DUSP2 expression by disrupting the DNTTIP1/HDAC1 complex.\",\n      \"method\": \"ChIP assay (HDAC1 at DUSP2 promoter), co-IP (DNTTIP1-HDAC1 interaction), luciferase reporter, western blot, in vitro/in vivo metastasis assays\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP and co-IP establishing epigenetic mechanism at DUSP2 promoter, functional rescue, multiple orthogonal methods\",\n      \"pmids\": [\"35689852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DUSP2 competes with AKT1 to bind casein kinase 2 alpha 1 (CSNK2A1), thereby inhibiting AKT1 phosphorylation and promoting apoptosis in pancreatic cancer. Activated AKT1 in turn induces TRIM21 E3 ubiquitin ligase to bind and mediate ubiquitination-dependent proteasomal degradation of DUSP2, forming a positive feedback loop that suppresses DUSP2.\",\n      \"method\": \"Co-immunoprecipitation (DUSP2-CSNK2A1, AKT1-CSNK2A1, TRIM21-DUSP2), ubiquitination assay, in vitro and in vivo apoptosis assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP for multiple binding partners with functional readout, ubiquitination assay, single lab\",\n      \"pmids\": [\"37390887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hypoxia-induced downregulation of DUSP2 promotes IL-6 expression in endometriotic stromal cells, which in turn activates STAT3 phosphorylation; DUSP2 overexpression suppresses IL-6 and phospho-STAT3 levels, and DUSP2 knockdown phenocopies hypoxia-induced IL-6 upregulation, establishing a DUSP2/IL-6/STAT3 axis in endometriosis.\",\n      \"method\": \"DUSP2 knockdown/overexpression, IL-6 quantification, STAT3 phosphorylation western blot, genome-wide expression profiling, BrdU proliferation assay\",\n      \"journal\": \"American journal of reproductive immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown/overexpression with mechanistic biochemical readouts, single lab\",\n      \"pmids\": [\"28440564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Membrane cholesterol loss during aging activates a subset of receptor tyrosine kinases (RTKs), increasing p38 MAPK activity, which in turn upregulates DUSP2 expression and activity in the hippocampus; this forms a negative-feedback loop that keeps p38 MAPK activity within physiological range during normal aging.\",\n      \"method\": \"Membrane cholesterol manipulation (enrichment/depletion), western blot for p38 phosphorylation and DUSP2 levels in aged mouse hippocampus, RTK inhibitor experiments\",\n      \"journal\": \"Frontiers in neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway dissection with pharmacological and biochemical methods, single lab\",\n      \"pmids\": [\"31293510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DUSP2 deletion by CRISPR/Cas9 in zebrafish promotes Mauthner cell axonal regeneration at early developmental stages; DUSP2 acts as a negative regulator of axon regeneration by mediating dephosphorylation of JNK, and DUSP2 knockout slightly increases phosphorylated JNK levels. Overexpression of DUSP2 retards M-cell axon regeneration.\",\n      \"method\": \"CRISPR/Cas9 knockout, single-cell electroporation for DUSP2 overexpression, western blot for phospho-JNK, axon regeneration imaging in Tg zebrafish\",\n      \"journal\": \"Neural regeneration research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and overexpression with defined phenotype and biochemical JNK readout, single lab\",\n      \"pmids\": [\"36018180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The RB/TRIM24 complex functions through DUSP2 as an intermediate bridge to activate the mTOR pathway in castration-resistant prostate cancer; TRIM24 transcriptional activity regulated at RB S249/T252 sites controls DUSP2 to promote mTOR signaling and prostate cancer progression.\",\n      \"method\": \"FXXXV motif mapping, co-immunoprecipitation (RB-TRIM24-DUSP2), mTOR pathway assays, PROTAC-mediated TRIM24 degradation\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP establishing ternary complex, functional mTOR pathway readout, single lab\",\n      \"pmids\": [\"38514847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DUSP2 inhibits STAT3 phosphorylation in vivo (AAV-DUSP2 overexpression in MRL/lpr lupus nephritis mice reduces STAT3 phosphorylation) and ameliorates lupus nephritis by reducing proteinuria, inflammatory cytokines (TNF-α, IL-6, IL-1β), and renal tissue injury.\",\n      \"method\": \"AAV-mediated DUSP2 overexpression in MRL/lpr mice, western blot for STAT3 phosphorylation, proteinuria and cytokine measurement, histopathology\",\n      \"journal\": \"Open life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo overexpression with biochemical STAT3 phosphorylation readout, single lab\",\n      \"pmids\": [\"37483429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"E2F4 transcription factor binds to the DUSP2 promoter and suppresses DUSP2 expression (validated by dual-luciferase reporter and ChIP assay); DUSP2 knockdown upregulates p38 MAPK phosphorylation and promotes endothelial cell proliferation, migration, and angiogenesis under high-glucose conditions.\",\n      \"method\": \"Dual-luciferase reporter, chromatin immunoprecipitation (ChIP), western blot for p-p38 MAPK, cell proliferation/migration/tube formation assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms E2F4 at DUSP2 promoter, functional p38 pathway readout, single lab\",\n      \"pmids\": [\"37479052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FBXO45 interacts with and ubiquitinates DUSP2, leading to its proteasomal degradation and subsequent ERK1/2 activation and enhanced glycolysis in cervical cancer cells (confirmed by co-IP and western blot); negative correlation between FBXO45 and DUSP2 was confirmed in tissue microarrays.\",\n      \"method\": \"Co-immunoprecipitation (FBXO45-DUSP2), ubiquitination assay, western blot for DUSP2 levels and ERK1/2 phosphorylation, Seahorse glycolysis assay, mouse xenograft model\",\n      \"journal\": \"Naunyn-Schmiedeberg's archives of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and ubiquitination assay with functional ERK/glycolysis readout, single lab\",\n      \"pmids\": [\"40637745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NELFCD recruits PRMT5 to the DUSP2 promoter (confirmed by co-IP and ChIP), suppressing DUSP2 expression and consequently activating p38 MAPK signaling to promote colon cancer cell growth.\",\n      \"method\": \"Co-immunoprecipitation (NELFCD-PRMT5), ChIP (PRMT5 at DUSP2 promoter), RNA sequencing, DUSP2 promoter ChIP-seq, cell proliferation assays\",\n      \"journal\": \"Frontiers in bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and ChIP establishing transcriptional repression mechanism, functional p38 readout, single lab\",\n      \"pmids\": [\"40302325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A variant of PAC-1 (DUSP2) identified in LGL leukemia encodes a 170-amino acid truncated protein (clone 8) lacking the phosphatase active site; when expressed as a GST fusion, this variant has no intrinsic phosphatase activity in vitro but enhances the phosphatase activity of co-added dual-specificity phosphatase CL100.\",\n      \"method\": \"cDNA library screening, GST-fusion protein expression in E. coli, in vitro phosphatase assay\",\n      \"journal\": \"Protein expression and purification\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — in vitro assay of variant protein, single lab, functional significance unclear\",\n      \"pmids\": [\"14680939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"IFN-I signaling in pre-exhausted T cells induces DUSP2 expression, which promotes NFAT dephosphorylation and nuclear accumulation; nuclear NFAT upregulates inhibitory receptors and antagonizes Bcl6-dependent transcriptional programs, reinforcing T cell exhaustion and impairing Tfh differentiation. Genetic ablation of Dusp2 restored CD8+ T cell function and Tfh-B cell interaction, enhancing ICB responsiveness in lung squamous carcinoma.\",\n      \"method\": \"Single-cell RNA sequencing, Dusp2 genetic ablation, NFAT phosphorylation assay, T cell functional assays, ICB treatment in Dusp2-KO mice\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined mechanistic NFAT dephosphorylation readout, single lab, scRNA-seq corroboration\",\n      \"pmids\": [\"41883167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Flavescensine 10 exhibits a potential interaction with DUSP2 and inhibits its expression, suppressing DUSP2-mediated mitochondrial apoptosis via the PI3K/Akt/JNK pathway in APAP-induced liver injury.\",\n      \"method\": \"In vitro hepatoprotection assay, in vivo APAP liver injury model, western blot for DUSP2, PI3K/Akt/JNK pathway analysis\",\n      \"journal\": \"Acta pharmaceutica Sinica B\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological inhibition of DUSP2 with pathway readout but no direct binding confirmation, single lab\",\n      \"pmids\": [\"41909738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Multiple oncogenic microRNA clusters (miR-17-92, miR-106a-363, miR-106b-25) directly target the DUSP2 mRNA 3'UTR (confirmed by reporter gene assay); specific miRNA inhibitors (miR-17-5p, miR-20b-5p, miR-106b-5p) increase DUSP2 mRNA levels in lymphoma cells, implicating miRNA-mediated DUSP2 suppression in MAPK pathway dysregulation in cancer.\",\n      \"method\": \"Reporter gene assay for 3'UTR interaction, pan-cancer expression correlation analysis, miRNA inhibitor treatment with qPCR\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct 3'UTR reporter assay validates miRNA binding, functional mRNA level change confirmed, single lab\",\n      \"pmids\": [\"40537745\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DUSP2 (PAC-1) is a mitogen-inducible, nuclear-localized dual-specificity MAP kinase phosphatase that preferentially dephosphorylates ERK2 (requiring ERK2 binding for catalytic activation), as well as ERK3, ERK4, STAT3, and STAT1; its expression is transcriptionally induced by the ERK/MAPK pathway itself (negative feedback) and is epigenetically silenced in multiple cancers via HDAC recruitment or miRNA targeting; it acts as a positive regulator of inflammatory signaling in immune cells (through ERK/p38/JNK crosstalk), a negative regulator of TH17 differentiation and T cell exhaustion (via STAT3 and NFAT dephosphorylation), and a suppressor of tumor stemness, metastasis, and drug resistance (through control of COX-2/PGE2, VEGF-C secretion, and AKT1 signaling), while its protein stability is regulated by TRIM21- and FBXO45-mediated ubiquitination and proteasomal degradation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"DUSP2 (PAC-1) is a mitogen-inducible, nuclear dual-specificity MAP kinase phosphatase originally cloned from human T cells and expressed predominantly in hematopoietic tissues [#0]. Its catalytic activity is conformationally gated: recombinant DUSP2 is essentially inactive alone and is allosterically activated upon association of its N-terminal kinase-binding domain with ERK2, a process coupled to a MAPK-induced rearrangement of the C-terminal phosphatase active site, with Arg294/Arg295 forming the phosphothreonine-binding pocket required for catalysis [#3, #4]. Through this binding-dependent mechanism DUSP2 preferentially dephosphorylates ERK2 while showing distinct handling of other MAPKs, and it engages the atypical kinases ERK3 and ERK4 via a KIM/CD-domain interaction that both dephosphorylates them, blocking downstream MK5 activation, and reciprocally stabilizes DUSP2 protein [#4, #9]. DUSP2 transcription is driven by the ERK/MAPK pathway itself, placing ERK2 upstream of PAC-1 induction and establishing a MAPK negative-feedback loop [#1]. Beyond MAPKs, DUSP2 directly binds and dephosphorylates STAT3 (Tyr705 and Ser727) and STAT1, and modulates NFAT phosphorylation, linking it to transcriptional control of inflammatory and effector programs [#8, #16, #28]. Genetic loss-of-function studies show DUSP2 is a positive regulator of inflammatory signaling via JNK/ERK crosstalk in arthritis models [#5], a negative regulator of TH17 differentiation [#8], a restrictor of STAT1-driven GSDMD pyroptosis in acute kidney injury [#16], and an enforcer of T cell exhaustion downstream of type I interferon through NFAT [#28]. In cancer, DUSP2 acts as a tumor suppressor whose silencing—via hypoxia/HIF-1, HDAC recruitment to its promoter, transcription-factor repression, or oncogenic miRNA targeting—drives ERK or p38 reactivation, stemness, EMT, metastasis, VEGF-C secretion, and drug resistance [#10, #11, #12, #17]. DUSP2 protein abundance is further controlled by ubiquitin-dependent proteasomal degradation through the E3 ligases TRIM21 and FBXO45 [#18, #25].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established the existence and basic identity of DUSP2 by cloning a mitogen-induced nuclear phosphatase, defining where and when it is expressed.\",\n      \"evidence\": \"cDNA cloning from human T cells with transfection-based subcellular localization in COS-7 and stimulated T cells\",\n      \"pmids\": [\"7681221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate specificity not yet defined\", \"Catalytic mechanism unresolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined DUSP2 as a MAP-kinase-directed dual-specificity phosphatase that downregulates signal transduction and mapped the gene, framing its negative-regulatory role.\",\n      \"evidence\": \"Genomic structure analysis and chromosomal mapping with functional description\",\n      \"pmids\": [\"7590752\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific MAPK substrate preference not distinguished\", \"No structural basis for specificity\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Showed DUSP2 transcription is itself driven by the ERK/MAPK pathway, establishing a negative-feedback architecture rather than constitutive expression.\",\n      \"evidence\": \"Promoter-reporter assays with dominant-negative ERK2 and EMSA for E-box/AP-2 elements\",\n      \"pmids\": [\"8649402\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of trans-acting factors at E-box/AP-2 sites not resolved\", \"Does not address protein-level feedback\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Provided the structural and mechanistic basis for catalysis, showing the active site is reconfigured by N-/C-domain interaction coupled to MAPK binding.\",\n      \"evidence\": \"NMR solution structure of the C-terminal phosphatase domain with biochemical phosphatase assays\",\n      \"pmids\": [\"12575935\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full-length structure with bound ERK2\", \"Dynamics of activation not directly visualized\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined substrate specificity and the substrate-induced activation mechanism, showing DUSP2 is inactive alone and requires ERK2 binding plus an intact phosphothreonine pocket.\",\n      \"evidence\": \"In vitro reconstitution with recombinant proteins, binding assays, and Arg294/Arg295 mutagenesis\",\n      \"pmids\": [\"16288922\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-cell substrate repertoire beyond ERK2 not addressed\", \"Quantitative selectivity over other DUSPs unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed an unexpected in vivo role as a positive regulator of inflammation through MAPK crosstalk, complicating the simple negative-feedback model.\",\n      \"evidence\": \"Dusp2-/- mice in the K/BxN arthritis model with kinase activity and transcription-factor reporter assays\",\n      \"pmids\": [\"16474395\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of JNK/ERK/p38 crosstalk not fully mechanistic\", \"Cell-type-specific contributions not separated\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Connected DUSP2 to receptor-driven feedback inhibition, showing it is recruited to ERK to terminate B-cell signaling.\",\n      \"evidence\": \"Co-IP of ERK with PAC-1 and phosphatase assays following BCR/FcgammaRIIb or ES-62 priming\",\n      \"pmids\": [\"11390499\", \"14607277\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab co-IP without reciprocal genetic validation\", \"Recruitment mechanism not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended DUSP2 substrates beyond MAPKs to STAT3, defining a direct route by which it restrains TH17 differentiation.\",\n      \"evidence\": \"Reciprocal co-IP, direct dephosphorylation assays, and Dusp2-/- colitis model with flow cytometry\",\n      \"pmids\": [\"26479789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT3 dephosphorylation is nuclear or cytoplasmic not resolved\", \"Selectivity for Tyr705 vs Ser727 kinetics unquantified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established DUSP2 regulation of the atypical kinases ERK3/ERK4 via KIM/CD docking, with reciprocal stabilization of DUSP2, broadening its substrate range.\",\n      \"evidence\": \"Co-IP, domain-mapped binding, dephosphorylation and protein-stability assays, MK5 activation readout\",\n      \"pmids\": [\"28252035\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological consequence of ERK3/ERK4 dephosphorylation in vivo unknown\", \"Mechanism of ERK4-dependent DUSP2 stabilization not detailed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined DUSP2 as a hypoxia-suppressed tumor suppressor whose loss elevates COX-2/PGE2 to drive cancer stemness.\",\n      \"evidence\": \"DUSP2 knockdown/overexpression, COX-2/PGE2 pathway perturbation, stemness assays, genome-wide profiling\",\n      \"pmids\": [\"28652251\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct link from DUSP2 phosphatase activity to COX-2 transcription not established\", \"Single-lab loss-of-function\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked DUSP2 loss to ERK reactivation and drug resistance/inflammation across tissue contexts, positioning it downstream of HIF-1.\",\n      \"evidence\": \"DUSP2 overexpression/knockdown rescue with HIF-1 manipulation in breast cancer and endometriotic stromal cell models\",\n      \"pmids\": [\"25596742\", \"28440564\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct substrate engagement (ERK vs STAT3) context-dependent and not always shown\", \"Single-lab epistasis\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated post-transcriptional silencing of DUSP2 by oncogenic miRNAs that activates ERK to drive EMT and metastasis.\",\n      \"evidence\": \"3'UTR luciferase, Ago2 co-IP, and DUSP2 rescue in pancreatic cancer; later extended to lymphoma miRNA clusters\",\n      \"pmids\": [\"30042387\", \"40537745\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of each miRNA in vivo unclear\", \"Whether miRNA loss restores DUSP2 function physiologically untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified a non-canonical route by which DUSP2 loss promotes EV-associated VEGF-C secretion and lymphovascular invasion in PDAC.\",\n      \"evidence\": \"Tissue-specific Dusp2 knockout mouse, EV isolation with VEGF-C quantification, lymphatic endothelial assays\",\n      \"pmids\": [\"32341770\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphatase substrate driving convertase/trafficking changes not identified\", \"Single-lab mechanism\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed DUSP2 restrains STAT1-driven GSDMD pyroptosis, defining a protective role in acute kidney injury and a STAT1 substrate.\",\n      \"evidence\": \"RTEC-specific Dusp2 conditional knockout, STAT1 phosphorylation and GSDMD transcription analysis, AAV rescue\",\n      \"pmids\": [\"35836796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct dephosphorylation of STAT1 by DUSP2 not shown in vitro\", \"Tissue specificity of STAT1 vs STAT3 preference unexplained\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established epigenetic silencing of DUSP2 via HDAC1 recruitment to its promoter, linking chromatin state to ERK reactivation in metastasis.\",\n      \"evidence\": \"ChIP, co-IP of DNTTIP1-HDAC1, luciferase, and metastasis assays with chidamide rescue\",\n      \"pmids\": [\"35689852\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HDAC silencing operates in non-NPC contexts not tested\", \"Upstream signal controlling DNTTIP1/HDAC1 recruitment unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified ubiquitin-dependent control of DUSP2 stability and a competitive AKT1/CSNK2A1 mechanism, embedding DUSP2 in a self-reinforcing degradation loop.\",\n      \"evidence\": \"Co-IP of DUSP2-CSNK2A1, AKT1-CSNK2A1, TRIM21-DUSP2 and ubiquitination/apoptosis assays in pancreatic cancer\",\n      \"pmids\": [\"37390887\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TRIM21 ubiquitination site on DUSP2 not mapped\", \"Single-lab multi-partner co-IP\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Reinforced DUSP2 as a STAT3-pathway suppressor in autoimmune disease and tied additional transcription factors to its promoter repression.\",\n      \"evidence\": \"AAV-DUSP2 overexpression in lupus nephritis mice; E2F4 ChIP/luciferase at the DUSP2 promoter with p38 readout\",\n      \"pmids\": [\"37483429\", \"37479052\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect STAT3 effects in vivo not separated\", \"Generality of E2F4 repression across tissues untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Placed DUSP2 as an intermediate in an RB/TRIM24-mTOR signaling axis driving castration-resistant prostate cancer progression.\",\n      \"evidence\": \"Motif mapping, co-IP of the RB-TRIM24-DUSP2 complex, mTOR pathway assays, PROTAC TRIM24 degradation\",\n      \"pmids\": [\"38514847\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How DUSP2 phosphatase activity connects to mTOR not mechanistically defined\", \"Single-lab ternary-complex evidence\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed DUSP2 enforces T cell exhaustion downstream of type I interferon via NFAT dephosphorylation, identifying it as an immunotherapy target.\",\n      \"evidence\": \"scRNA-seq, Dusp2 genetic ablation, NFAT phosphorylation and T cell function assays, ICB treatment in vivo\",\n      \"pmids\": [\"41883167\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DUSP2-NFAT dephosphorylation kinetics not characterized\", \"Single tumor model\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Added FBXO45 as a second E3 ligase degrading DUSP2 to sustain ERK-driven glycolysis, and broadened the degradation/silencing landscape.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, ERK1/2 and Seahorse glycolysis readouts, xenograft, plus NELFCD/PRMT5 promoter repression\",\n      \"pmids\": [\"40637745\", \"40302325\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Hierarchy/redundancy between TRIM21 and FBXO45 unknown\", \"Degradation site on DUSP2 not mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How DUSP2 selects among ERK, STAT, and NFAT substrates in a given cell type, and how its many transcriptional/epigenetic/post-translational repressors are integrated, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of substrate selection across contexts\", \"Relative weight of transcriptional vs degradative control unquantified\", \"No full-length DUSP2-substrate complex structure\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 2, 3, 4]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [4, 8, 9, 16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 4, 9]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 8, 28]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 11, 17, 25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ERK2\", \"ERK3\", \"ERK4\", \"STAT3\", \"STAT1\", \"CSNK2A1\", \"TRIM21\", \"FBXO45\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":7,"faith_total":8,"faith_pct":87.5}}